Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%
May 01
Swiss (SMI) Biotech Industry Analysis
UpdatedMay 18, 2024
DataAggregated Company Financials
Companies7
- 7D6.7%
- 3M4.6%
- 1Y23.4%
- YTD29.2%
The Biotech industry is up 6.7% in the last week, with Kuros Biosciences up 11%. Meanwhile, Addex Therapeutics actually underperformed within the industry, shrinking 6.8% in the last week. This takes the industry's 12 month performance to a gain of 23%. Looking forward, earnings are forecast to grow by 13% annually.
Industry Valuation and Performance
Has the Swiss Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 18 May 2024 | CHF538.2m | CHF170.7m | -CHF134,962,764.00 | 1x | -4x | 3.2x |
| Mon, 15 Apr 2024 | CHF451.9m | CHF67.6m | -CHF173,099,120.58 | 0.1x | -2.6x | 6.7x |
| Wed, 13 Mar 2024 | CHF355.5m | CHF55.5m | -CHF173,258,224.22 | 0.3x | -2.1x | 6.4x |
| Fri, 09 Feb 2024 | CHF365.6m | CHF55.4m | -CHF173,287,535.62 | 1x | -2.1x | 6.6x |
| Sun, 07 Jan 2024 | CHF324.0m | CHF317.4m | -CHF176,097,332.00 | 0.5x | -1.8x | 1x |
| Tue, 05 Dec 2023 | CHF340.1m | CHF317.8m | -CHF208,920,007.00 | n/a | -1.6x | 1.1x |
| Thu, 02 Nov 2023 | CHF253.7m | CHF318.6m | -CHF211,518,481.00 | n/a | -1.2x | 0.8x |
| Sat, 30 Sep 2023 | CHF262.4m | CHF318.8m | -CHF219,583,688.00 | n/a | -1.2x | 0.8x |
| Mon, 28 Aug 2023 | CHF302.2m | CHF318.7m | -CHF188,690,006.00 | n/a | -1.6x | 0.9x |
| Wed, 26 Jul 2023 | CHF349.3m | CHF322.2m | -CHF179,787,126.00 | n/a | -1.9x | 1.1x |
| Fri, 23 Jun 2023 | CHF303.9m | CHF331.2m | -CHF180,833,676.00 | n/a | -1.7x | 0.9x |
| Sun, 21 May 2023 | CHF351.7m | CHF331.2m | -CHF183,199,380.00 | n/a | -1.9x | 1.1x |
| Tue, 18 Apr 2023 | CHF425.1m | CHF481.3m | CHF8.2m | 1.5x | 51.9x | 0.9x |
| Thu, 16 Mar 2023 | CHF422.9m | CHF494.3m | CHF15.0m | 1.5x | 28.2x | 0.9x |
| Sat, 11 Feb 2023 | CHF483.0m | CHF493.4m | CHF14.5m | 1.7x | 33.3x | 1x |
| Mon, 09 Jan 2023 | CHF503.1m | CHF493.4m | CHF14.5m | 1.6x | 34.7x | 1x |
| Wed, 07 Dec 2022 | CHF513.1m | CHF493.4m | CHF14.5m | 1.8x | 35.4x | 1x |
| Fri, 04 Nov 2022 | CHF508.5m | CHF509.5m | CHF14.9m | 1.8x | 34.2x | 1x |
| Sun, 02 Oct 2022 | CHF521.6m | CHF505.3m | CHF15.9m | 2x | 32.8x | 1x |
| Tue, 30 Aug 2022 | CHF519.6m | CHF497.9m | CHF36.7m | 1.7x | 14.1x | 1x |
| Thu, 28 Jul 2022 | CHF518.1m | CHF487.8m | CHF42.2m | 1.8x | 12.3x | 1.1x |
| Sat, 25 Jun 2022 | CHF540.7m | CHF454.1m | CHF80.7m | 2.1x | 6.7x | 1.2x |
| Mon, 23 May 2022 | CHF719.6m | CHF471.4m | CHF25.1m | 2.1x | 28.6x | 1.5x |
| Wed, 20 Apr 2022 | CHF1.1b | CHF293.2m | -CHF142,349,433.00 | 1.5x | -7.4x | 3.6x |
| Fri, 18 Mar 2022 | CHF1.2b | CHF284.2m | -CHF137,157,645.00 | 2x | -8.9x | 4.3x |
| Sun, 13 Feb 2022 | CHF1.4b | CHF282.9m | -CHF138,870,474.00 | 1.8x | -10x | 4.9x |
| Tue, 11 Jan 2022 | CHF4.7b | CHF319.0m | -CHF658,800,255.00 | 1.5x | -7.2x | 14.9x |
| Thu, 09 Dec 2021 | CHF4.0b | CHF318.2m | -CHF658,916,973.00 | 1.5x | -6x | 12.4x |
| Sat, 06 Nov 2021 | CHF4.3b | CHF315.0m | -CHF658,980,102.00 | 2.3x | -6.6x | 13.7x |
| Mon, 04 Oct 2021 | CHF5.1b | CHF288.3m | -CHF590,726,662.00 | 4.9x | -8.7x | 17.8x |
| Wed, 01 Sep 2021 | CHF5.3b | CHF306.0m | -CHF612,309,374.80 | 1.1x | -8.6x | 17.3x |
| Thu, 08 Jul 2021 | CHF5.8b | CHF306.0m | -CHF612,309,374.80 | 1.1x | -9.4x | 18.8x |
Price to Earnings Ratio
-10.8x
Current Industry PE
- Investors are pessimistic on the Swiss Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.2x is higher than the industry's current PS ratio of 3.2x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 21% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Swiss Healthcare industry?
| CH Market | 1.97% | |
| Healthcare | 3.33% | |
| Biotech | 6.68% | |
| Biotech | 6.68% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| KURN Kuros Biosciences | CHF7.96 | 11.3% +CHF29.9m | 483.2% | PS8.8x | |
| IDIA Idorsia | CHF2.22 | 2.8% +CHF10.7m | -73.9% | PS2.2x | |
| BSLN Basilea Pharmaceutica | CHF43.65 | 1.6% +CHF8.5m | -6.1% | PE50.4x | |
| MOLN Molecular Partners | CHF3.31 | 2.2% +CHF2.3m | -45.6% | PS15.6x | |
| SANN Santhera Pharmaceuticals Holding | CHF9.25 | 0.9% +CHF905.6k | 49.0% | PE1.9x |